Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Warning over Champix suicide risk

  • Comment

Europe's drugs watchdog has issued a warning over suicidal ideations and attempts among patients taking stop-smoking medicine varenicline (Champix).

The European Medicines Agency issued the warning after monitoring varenicline since it was licensed for use in the European Union in September last year.

Its Committee for Medicinal Products for Human Use (CHMP) has analysed all adverse reactions to the drug.

At its meeting this month, the CHMP decided to warn doctors that depression has been reported in patients who are trying to stop smoking using varenicline.

Symptoms of this depression may include suicidal ideation and suicide attempts, the committee said. It requested that its manufacturer, Pfizer, revises product information accordingly to warn doctors and patients.

A spokesperson added: 'The EMEA will continue to keep this issue and take appropriate actions if further concerns arise.'

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs